RA
BBIO icon

Royce & Associates’s BridgeBio Pharma BBIO Stock Holding History

Royce & Associates’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
218,487
-14,436
-6% -$1.01M 0.13% 261
2026
Q1 		$17.3M Hold
232,923
– – 0.17% 182
2025
Q4 		$17.8M Hold
232,923
– – 0.18% 175
2025
Q3 		$12.1M Buy
232,923
+10,618
+5% +$518K 0.12% 254
2025
Q2 		$9.6M Buy
222,305
+30,523
+16% +$1.11M 0.1% 298
2025
Q1 		$6.63M Buy
191,782
+46,994
+32% +$1.58M 0.07% 387
2024
Q4 		$3.97M Buy
144,788
+22,833
+19% +$590K 0.04% 529
2024
Q3 		$3.1M Buy
+121,955
New +$3.2M 0.03% 558

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Royce & Associates's BBIO Position: Q2 2026 in Review

Royce & Associates reduced its BridgeBio Pharma (BBIO) stake by 6.2% in Q2 2026, selling an estimated $1.01M and leaving 218,487 shares worth $16.3M. The position accounts for 0.13% of the portfolio, ranked #261.

Royce & Associates first reported a position in BBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $17.8M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Royce & Associates held 218,487 shares of BridgeBio Pharma worth $16.3M as of Q2 2026.
  • Royce & Associates sold 14,436 BridgeBio Pharma shares in Q2 2026, an estimated $1.01M.
  • BridgeBio Pharma made up 0.13% of Royce & Associates's portfolio in Q2 2026, its #261 holding.
  • Royce & Associates first reported a position in BridgeBio Pharma in Q3 2024 and has held it in 8 quarters since.
  • Royce & Associates's BridgeBio Pharma position peaked at $17.8M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.